NCIt related terms : MET tyrosine kinase inhibitor PF-02341066; PF-02341066;
NCIt definition : An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase
anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR)
with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and
inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met
kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits
tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important
role in nervous system development. ALK dysregulation and gene rearrangements are
associated with a series of tumors.;
Alternative definition : NCI-GLOSS: A substance being studied in the treatment of some types of cancer. It
blocks enzymes that cancer cells need to grow and spread. It may also prevent the
growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase
inhibitor and a type of antiangiogenesis agent.;
UNII : 53AH36668S;
InChIKey : KTEIFNKAUNYNJU-GFCCVEGCSA-N;
CAS number : 877399-52-5; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 877399-52-5
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Drug name : Xalkori;
Molecule name : PF-2341066; PF02341066;
Chemical formula : C21H22Cl2FN5O;
ChEBI ID : CHEBI:64310;
Codes from synonyms : CDR0000658849; CDR0000658850; 119;